PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
NBIX vs. UTHR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

NBIX vs. UTHR

Last updated May 13, 2025

Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBIX or UTHR.

Correlation

The correlation between NBIX and UTHR is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

NBIX vs. UTHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

NBIX:

-0.29

UTHR:

0.56

Sortino Ratio

NBIX:

-0.16

UTHR:

0.97

Omega Ratio

NBIX:

0.97

UTHR:

1.14

Calmar Ratio

NBIX:

-0.31

UTHR:

0.60

Martin Ratio

NBIX:

-0.70

UTHR:

1.41

Ulcer Index

NBIX:

19.10%

UTHR:

13.52%

Daily Std Dev

NBIX:

41.81%

UTHR:

31.61%

Max Drawdown

NBIX:

-97.21%

UTHR:

-93.18%

Current Drawdown

NBIX:

-21.44%

UTHR:

-24.20%

Fundamentals

Market Cap

NBIX:

$11.45B

UTHR:

$14.02B

EPS

NBIX:

$2.95

UTHR:

$25.11

PE Ratio

NBIX:

39.22

UTHR:

12.38

PEG Ratio

NBIX:

0.27

UTHR:

1.43

PS Ratio

NBIX:

4.75

UTHR:

4.68

PB Ratio

NBIX:

4.75

UTHR:

2.00

Total Revenue (TTM)

NBIX:

$2.41B

UTHR:

$2.99B

Gross Profit (TTM)

NBIX:

$2.37B

UTHR:

$2.66B

EBITDA (TTM)

NBIX:

$539.80M

UTHR:

$1.56B

Returns By Period

The year-to-date returns for both stocks are quite close, with NBIX having a -11.77% return and UTHR slightly lower at -11.91%. Over the past 10 years, NBIX has outperformed UTHR with an annualized return of 11.24%, while UTHR has yielded a comparatively lower 6.07% annualized return.

NBIX

YTD

-11.77%

1M

32.53%

6M

-5.30%

1Y

-11.90%

5Y*

1.10%

10Y*

11.24%

UTHR

YTD

-11.91%

1M

10.54%

6M

-22.39%

1Y

17.61%

5Y*

22.51%

10Y*

6.07%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Risk-Adjusted Performance

NBIX vs. UTHR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
NBIX
The Risk-Adjusted Performance Rank of NBIX is 3131
Overall Rank
The Sharpe Ratio Rank of NBIX is 3434
Sharpe Ratio Rank
The Sortino Ratio Rank of NBIX is 3131
Sortino Ratio Rank
The Omega Ratio Rank of NBIX is 3030
Omega Ratio Rank
The Calmar Ratio Rank of NBIX is 2828
Calmar Ratio Rank
The Martin Ratio Rank of NBIX is 3333
Martin Ratio Rank
UTHR
The Risk-Adjusted Performance Rank of UTHR is 6969
Overall Rank
The Sharpe Ratio Rank of UTHR is 7272
Sharpe Ratio Rank
The Sortino Ratio Rank of UTHR is 6666
Sortino Ratio Rank
The Omega Ratio Rank of UTHR is 6767
Omega Ratio Rank
The Calmar Ratio Rank of UTHR is 7474
Calmar Ratio Rank
The Martin Ratio Rank of UTHR is 6767
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NBIX vs. UTHR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NBIX Sharpe Ratio is -0.29, which is lower than the UTHR Sharpe Ratio of 0.56. The chart below compares the historical Sharpe Ratios of NBIX and UTHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Dividends

NBIX vs. UTHR - Dividend Comparison

Neither NBIX nor UTHR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NBIX vs. UTHR - Drawdown Comparison

The maximum NBIX drawdown since its inception was -97.21%, roughly equal to the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for NBIX and UTHR. For additional features, visit the drawdowns tool.

Loading data...

Volatility

NBIX vs. UTHR - Volatility Comparison

Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 11.22% compared to United Therapeutics Corporation (UTHR) at 7.80%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...

Financials

NBIX vs. UTHR - Financials Comparison

This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and United Therapeutics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

200.00M300.00M400.00M500.00M600.00M700.00M800.00M20212022202320242025
572.60M
794.40M
(NBIX) Total Revenue
(UTHR) Total Revenue
Values in USD except per share items

NBIX vs. UTHR - Profitability Comparison

The chart below illustrates the profitability comparison between Neurocrine Biosciences, Inc. and United Therapeutics Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.
Gross Margin
Operating Margin
Net Margin
Quarterly
Annual
88.0%90.0%92.0%94.0%96.0%98.0%100.0%20212022202320242025
98.4%
88.4%
(NBIX) Gross Margin
(UTHR) Gross Margin
NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a gross profit of 563.40M and revenue of 572.60M. Therefore, the gross margin over that period was 98.4%.

UTHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, United Therapeutics Corporation reported a gross profit of 701.90M and revenue of 794.40M. Therefore, the gross margin over that period was 88.4%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported an operating income of 23.60M and revenue of 572.60M, resulting in an operating margin of 4.1%.

UTHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, United Therapeutics Corporation reported an operating income of 382.80M and revenue of 794.40M, resulting in an operating margin of 48.2%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a net income of 7.90M and revenue of 572.60M, resulting in a net margin of 1.4%.

UTHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, United Therapeutics Corporation reported a net income of 322.20M and revenue of 794.40M, resulting in a net margin of 40.6%.